TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11607883
Drug: SRL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL treatment before surgery
Study: 7811540
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to didanosine after prior zidovudine therapy
Study: 3217412
Drug: Caffeine 8
Normalized name: caffeine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 8 mg/kg
Study: 26232692
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository 2 hours before biopsy + 10 mL of 2% Xylocaine gel 5 minutes before biopsy
Study: 26232692
Drug: Xylocaine gel
Normalized name: Xylocaine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylocaine gel only
Study: 23116363
Drug: SCH 900435
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 900435 8 mg
Study: 23116363
Drug: SCH 900435
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 900435 12 mg
Study: 23116363
Drug: SCH 900435
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 900435 20 mg
Study: 23116363
Drug: SCH 900435
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 900435 30 mg
Study: 23116363
Drug: Multiple ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending dose study
Study: 14743096
Drug: Extubation relayed
Normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extubation relayed by nasal oxygen therapy (group B)
Study: 23279632
Drug: doubling baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: doubling baseline statin (simvastatin 40 mg or atorvastatin 20 mg)
Study: 7862216
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2
Study: 6433769
Drug: HB 420
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HB 420 (3.5 mg)
Study: 30067074
Drug: GS100 (nonsystemic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS100 (nonsystemic, orally administered hydrogel) co-administered with metformin
Study: 16873952
Drug: Standard antiasthmatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiasthmatic therapy
Study: 11904108
Drug: Thyroxine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine treatment (50 to 100 microg daily)
Study: 8970936
Drug: Thyroxine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine treatment
Study: 10453443
Drug: Selected vegetables
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selected vegetables (SV) added to the daily diet of stage III and IV NSCLC patients (SVG group).
Study: 2083404
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (CMT, trilisate) pre-treatment at a dose of 3000 mg daily for 3 days
Study: 7459899
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (CTX)
Study: 31605663
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (3 months of supervised aerobic and resistance exercise training, twice a week for 60 min)
Study: 17121051
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI)
Study: 19463378
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus GP IIb/IIIa inhibitor (control) (n = 317)
Study: 10753259
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A therapy
Study: 25097088
Drug: Lidocaine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (50 mg)
Study: 25097088
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (0.25 mg)
Study: 25097088
Drug: Lidocaine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (50 mg) plus Magnesium sulfate (0.25 mg)
Study: 23051680
Drug: Home unattended
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home unattended portable monitoring and automatic CPAP titration
Study: 21743432
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=19) - received customary training in oral diagnosis
Study: 18231111
Drug: Transitions between
Normalized name: CONNECTOR,ENFIT TRANSITIONAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transitions between phases of treatment
Study: 14587168
Drug: Lytic or
Normalized name: pepsin/enzymes,digestive/whole bile/enzymes, proteolytic ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lytic or combination therapy for patients less than 75 years of age in hospitals unable to perform early PCI.
Study: 14587168
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy for patients older than 75 years unable to receive early PCI.
Study: 14587168
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using IIb/IIIa inhibitors plus fibrinolytics and/or LMWH.
Study: 8790090
Drug: Oral acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acyclovir, 400 mg, 5 times daily
Study: 6090019
Drug: Ceftizoxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime (2 gm/day, administered intravenously)
Study: 30878496
Drug: Robotic-assisted shoulder
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted shoulder rehabilitation therapy (30 minutes per day, 5 times per week for 4 weeks)
Study: 30866621
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy
Study: 30541622
Drug: Pre-cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-cognitive behavioural therapy digital 'informed choice' intervention
Study: 27653444
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg per day of azathioprine (AZA)
Study: 27653444
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg per day of azathioprine (AZA)
Study: 16007042
Drug: Framon (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Framon (0.25 mg/kg, intravenous bolus)
Study: 8964631
Drug: Bioelectrical impedance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioelectrical impedance analysis (BIA) at the end of treatment
Study: 7631946
Drug: 2% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% glucose in lactated Ringer's solution (D2LR)
Study: 7631946
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose in lactated Ringer's solution (D5LR)
Study: 2042756
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution alone (LR)
Study: 28914978
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 12.5 mg/kg twice daily for EGT carrier children
Study: 28914978
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 10.6 mg/kg twice daily for EGT noncarrier children
Study: 27102361
Drug: Curcumin (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1500 mg/d BiocurcumaxTM)
Study: 28313
Drug: Triazolam 0.5
Normalized name: triazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.5 mg (Halcion)
Study: 28075066
Drug: Alogliptin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin + Metformin FDC (12.5 mg + 500 mg BID)
Study: 28075066
Drug: Alogliptin (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (12.5 mg BID)
Study: 28394459
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg BID)
Study: 11185668
Drug: Pilocarpine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (single oral doses ranging from 2.5 to 20 mg)
Study: 6188892
Drug: Pirmenol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol (150 mg/30 min)
Study: 6188892
Drug: Lidocaine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (250 mg/30 min)
Study: 26856226
Drug: Edoxaban 60/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60/30 mg
Study: 19127595
Drug: Rasagiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (1 mg/day)
Study: 15856079
Drug: Sertraline or
Normalized name: sertraline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline or bupropion treatment for 5 weeks
Study: 11991878
Drug: Inhaled substance
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled substance P
Study: 11991878
Drug: Inhaled neurokinin
Normalized name: Neurokinin p
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled neurokinin A (Control)
Study: 19635615
Drug: BZA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZA (20 mg)/CE (0.625 or 0.45 mg)
Study: 15242359
Drug: Naftopidil (50-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil (50-75 mg daily)
Study: 15242359
Drug: Eviprostat (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eviprostat (six tablets daily)
Study: 11760371
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa 5 million units thrice weekly plus oral ribavirin 1,200 mg daily for 24 weeks (regimen A)
Study: 11760371
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa 5 million units thrice weekly plus oral ribavirin 1,200 mg daily for 24 weeks followed by interferon alfa 3 MU thrice weekly for another 24 weeks (regimen B)
Study: 9531230
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens 0.3 mg/d
Study: 9531230
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens 0.625 mg/d
Study: 9531230
Drug: Esterified estrogens
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogens 1.25 mg/d
Study: 26196502
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg daily) plus Sofosbuvir (400 mg daily) for 12 weeks
Study: 26196502
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg daily) plus Sofosbuvir (400 mg daily) for 8 weeks
Study: 16612142
Drug: Hydroalcoholic gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroalcoholic gels containing ibuprofen
Study: 12802750
Drug: IFN‐alpha‐2b monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha‐2b monotherapy (10 million U 3 times per week for 12 months)
Study: 11199949
Drug: Opipramol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opipramol (200 mg/day)
Study: 1386490
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 to 8 mg daily)
Study: 1386490
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 to 80 mg daily in slow-release form)
Study: 27809868
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (0.4 mg)
Study: 24632753
Drug: Lopinavir/ritonavir 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 400/100 mg twice a day plus nucleoside reverse transcriptase inhibitors
Study: 15490983
Drug: Imipenem/cilastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin monotherapy
Study: 1552197
Drug: Aminoglycoside therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside therapy
Study: 2571295
Drug: Angiotensin‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting enzyme inhibitors
Study: 22717418
Drug: IRO‐A 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRO‐A 1 × 5 mg
Study: 22717418
Drug: IRO‐A and
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRO‐A and IRO tablets (safety profile)
Study: 20379676
Drug: Control (C)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (C) - no surface treatment
Study: 18053120
Drug: 0.0125 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0125 mg/kg/d of GH subcutaneously added to standard therapy
Study: 8476802
Drug: 15 min
Normalized name: Carmex Daily Care Moisturizing Lip Balm SPF 15 Minis KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 min incremental oxytocin infusion
Study: 3774206
Drug: Pirenzepine (PRZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PRZ) 50 mg/day
Study: 3774206
Drug: Pirenzepine (PRZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PRZ) 100 mg/day
Study: 30232854
Drug: Medication (Metformin)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Metformin)
Study: 30304712
Drug: Greater injection
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater injection self-efficacy
Study: 27277211
Drug: Low protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protamine dosing (0.8 protamine-to-heparin ratio; n=49)
Study: 27277211
Drug: High protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protamine dosing (1.3 protamine-to-heparin ratio; n=47)
Study: 14696681
Drug: Acupressure at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure at Neiguan (PC-6), Zusanli (ST-36), and Sanyinjiao (SP-6) for 3 minutes, twice a day
Study: 8468440
Drug: moclobemide, 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide, 450 mg/day
Study: 3545141
Drug: Ketoconazole, 200
Normalized name: Ketoconazole, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole, 200 mg via the gastrointestinal tract daily for 21 days or until one week after discharge from the SICU.
Study: 16893381
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg
Study: 12145058
Drug: Tizanidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (4 mg)
Study: 8139083
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d of tacrine for 6 weeks, then 80 mg/d for 24 weeks
Study: 8139083
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d of tacrine for 6 weeks, 80 mg/d for 6 weeks, and 120 mg/d for 6 weeks
Study: 8707476
Drug: Tacrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine treatment
Study: 11897546
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg
Study: 12947359
Drug: Warfarin (dose-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose-adjusted to INR 2.0-3.0)
Study: 12947359
Drug: Ximelagatran (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (36 mg bid)
Study: 1867581
Drug: Nimorazole 1
Normalized name: nimorazole 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimorazole 1 g per day for 7 days (Group III)
Study: 6817770
Drug: Bupropion 100
Normalized name: buPROPion 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 100 mg + Diazepam 5 mg
Study: 25876339
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg tablet once every night for 4 weeks, increased to 10 mg tablet after 4 weeks)
Study: 22985998
Drug: Family-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused cognitive behaviour therapy (CBT)
Study: 29537447
Drug: Oxymetazoline cream
Normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline cream 1.0%
Study: 21879233
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation (PMR) therapy
Study: 14557446
Drug: Flutamide-metformin added
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide-metformin added to gestodene-containing OC in OC+ women
Study: 11783156
Drug: Yixin oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yixin oral liquid (YXOL)
Study: 11783156
Drug: Shuxinsu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxinsu capsule (SXSC) and openly treated group (OTG)
Study: 2196623
Drug: Fluoxetine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (various doses)
Study: 28808791
Drug: Control (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (25 mL soybean oil daily)
Study: 12687805
Drug: Lateral sites
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral sites (AL + L + PL CST, 134 patients)
Study: 6248395
Drug: Fenoterol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (5 mg)
Study: 24421266
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of APP before injection of polyI:C
Study: 22797003
Drug: β‐alanine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐alanine supplementation (BA, 2 × 800 mg tablets, 3 times daily)
Study: 22797003
Drug: Placebo (PL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL, 2 × 800 mg maltodextrin tablets, 3 times daily)
Study: 17359403
Drug: 1 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg(‐1) midazolam (group H)
Study: 17359403
Drug: 0.5 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg(‐1) midazolam (group L)
Study: 7613796
Drug: Indoramin (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (alpha 1-adrenergic blocker)
Study: 150142
Drug: Control preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control preparation (Betamethasone valerate + Gentamicin + Tolnaftate + Clioquinol)
Study: 25274197
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) and exercise
Study: 25274197
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (placebo HILT) and exercise
Study: 21109517
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment regimens for ANCA-associated vasculitis
Study: 17699491
Drug: Placebo (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3.6 g of granulate each day)
Study: 3986086
Drug: Alpha-methyldopa (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-methyldopa (750 mg)
Study: 29763353
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri probiotic lozenges (n = 90)
Study: 29763353
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges (n = 88)
Study: 28744807
Drug: Low-dose tranexamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tranexamic acid (5 mg/kg bolus loading dose and 1 mg/kg continuous infusion)
Study: 28744807
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (10 mg/kg bolus loading dose and 2 mg/kg continuous infusion)
Study: 23124782
Drug: PA21 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA21 10 g/d
Study: 23124782
Drug: PA21 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA21 12.5 g/d
Study: 23124782
Drug: PA21 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA21 5.0 g/d
Study: 23124782
Drug: PA21 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA21 7.5 g/d
Study: 23124782
Drug: Sevelamer-HCl 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer-HCl 4.8 g/d
Study: 10731543
Drug: Half-dose nafarelin
Normalized name: nafarelin Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose nafarelin treatment (200 microgram daily) for 20 weeks after 4 weeks of full-dose nafarelin (n = 8)
Study: 8736459
Drug: Betaxolol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol monotherapy (5-10 mg daily for 6 months)
Study: 8736459
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with betaxolol and nitrendipine (10-20 mg once daily from month 7 to 12)
Study: 20722793
Drug: Medicinal plants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicinal plants (e.g., Ferula hermonis, Angelica sinensis, Ginkgo biloba)
Study: 7956409
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefonicid daily intravenously started at chest tube insertion and stopped within 24 h of removal
Study: 7956409
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefonicid daily intravenously
Study: 2892450
Drug: Cetirizine 20
Normalized name: cetirizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 20 mg
Study: 2892450
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg
Study: 29877995
Drug: Web-based calculator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based calculator tool for communicating estimates of personalized treatment outcomes
Study: 18673417
Drug: Physiotherapy (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy (five times daily using inter-positioning tongue spatulas, adding a new spatula every 5-10 days)
Study: 18673417
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of hyaluronidase with steroids